国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
11期
1592-1593
,共2页
雷贝拉唑%铝碳酸镁%胃食管反流病
雷貝拉唑%鋁碳痠鎂%胃食管反流病
뢰패랍서%려탄산미%위식관반류병
Rabeprazole%Hydrotalcid%Gastroesophageal reflux disease
目的 评价雷贝拉唑联合铝碳酸镁治疗胃食管反流病的临床疗效.方法 选取2010年8月至2013年10月收治的胃食管反流病患者40例,随机分为两组,其中观察组20例,采用雷贝拉唑联合铝碳酸镁治疗;对照组20例,采用奥美拉唑联合阿莫西林治疗.用药4周后观察并比较两组患者的反流症状改善程度和食管pH变化.结果 观察组反流症状消失19例(95.0％),反流症状不消失1例(5.0％);对照组反流症状消失14例(70.0％),反流症状不消失6例(30.0％),两组患者反流症状改善程度比较差异有统计学意义(P＜0.05).食管pH ＜4观察组2例(10.0％),对照组5例(25.0％);食管pH ＞4观察组18例(90.0％),对照组15例(75％),两组患者食管pH值变化比较差异有统计学意义(P＜0.05).结论 雷贝拉唑联合铝碳酸镁治疗胃食管反流病的临床疗效好,值得在临床上予以推广.
目的 評價雷貝拉唑聯閤鋁碳痠鎂治療胃食管反流病的臨床療效.方法 選取2010年8月至2013年10月收治的胃食管反流病患者40例,隨機分為兩組,其中觀察組20例,採用雷貝拉唑聯閤鋁碳痠鎂治療;對照組20例,採用奧美拉唑聯閤阿莫西林治療.用藥4週後觀察併比較兩組患者的反流癥狀改善程度和食管pH變化.結果 觀察組反流癥狀消失19例(95.0％),反流癥狀不消失1例(5.0％);對照組反流癥狀消失14例(70.0％),反流癥狀不消失6例(30.0％),兩組患者反流癥狀改善程度比較差異有統計學意義(P＜0.05).食管pH ＜4觀察組2例(10.0％),對照組5例(25.0％);食管pH ＞4觀察組18例(90.0％),對照組15例(75％),兩組患者食管pH值變化比較差異有統計學意義(P＜0.05).結論 雷貝拉唑聯閤鋁碳痠鎂治療胃食管反流病的臨床療效好,值得在臨床上予以推廣.
목적 평개뢰패랍서연합려탄산미치료위식관반류병적림상료효.방법 선취2010년8월지2013년10월수치적위식관반류병환자40례,수궤분위량조,기중관찰조20례,채용뢰패랍서연합려탄산미치료;대조조20례,채용오미랍서연합아막서림치료.용약4주후관찰병비교량조환자적반류증상개선정도화식관pH변화.결과 관찰조반류증상소실19례(95.0％),반류증상불소실1례(5.0％);대조조반류증상소실14례(70.0％),반류증상불소실6례(30.0％),량조환자반류증상개선정도비교차이유통계학의의(P＜0.05).식관pH ＜4관찰조2례(10.0％),대조조5례(25.0％);식관pH ＞4관찰조18례(90.0％),대조조15례(75％),량조환자식관pH치변화비교차이유통계학의의(P＜0.05).결론 뢰패랍서연합려탄산미치료위식관반류병적림상료효호,치득재림상상여이추엄.
Objective To evaluate the clinical efficacy of rabeprazole combined with aluminum magnesium in gastroesophageal reflux disease treatment.Methods From August 2010 to October 2013 in our hospital,40 cases of gastroesophageal reflux disease were randomly divided into two groups,20 cases in observation group,using aluminum magnesium rabeprazole combination therapy,the control group with 20 cases used omeprazole amoxicillin treatment,the degree of improvement in reflux symptoms and esophageal pH changes in two groups were compared after 4 weeks.Results The reflux symptoms disappeared in 19 patients (95％),reflux symptoms did not disappear in 1 case (5％) in the control group reflux symptoms disappeared in 14 patients (70％),reflux symptoms did not disappear in 6 patients (30％),two reflux symptom improvement was statistically significantly different (P ＜ 0.05).In observation group 2 patients (10％) esophageal pH ＜ 4,18 patients (90％) esophageal pH ＞ 4,the control group 5 cases (25％) esophageal pH ＜ 4,15 patients (75％) pH ＞ 4,two esophagus pH changes showed statistical significant differences (P ＜ 0.05).Conclusion The combined aluminum magnesium rabeprazole therapy has good clinical efficacy in the treatment of gastroesophageal reflux disease,deserves to be promoted in clinical practice.
